ESR1 and neoplasm: However, no statistically significant BCSS difference was observed between ER-positive/PR-negative and ER-negative/PR-positive subtypes in male, black, tumor grade II, adjusted AJCC sixth edition stage IV, ILC, or mixed IDC/ILC subgroups (eTable 2 in the Supplement).